NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions

CancerNeoplasmsMetastatic CancerTriple Negative Breast CancerGastric CancerCervical CancerOvarian CancerHepatocellular CarcinomaSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaUrothelial NeoplasmNon Small Cell Lung CancerRenal Cell CarcinomaLocally Advanced Solid TumorLocally Advanced Malignant NeoplasmSquamous Cell CarcinomaSarcomaMerkel Cell CarcinomaBladder Cancer

Interventions

DRUG

OC-001

Administered IV.

DRUG

Drug: OC-001 in Combination with Avelumab

Administered IV.

Trial Locations (5)

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

Unknown

RECRUITING

Ottawa Hospital Cancer Centre (OHRI), Ottawa

M5G 2C1

RECRUITING

Princess Margaret Hospital, Toronto

H2X 0A9

RECRUITING

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

H3T 1E2

RECRUITING

Jewish General Hospital - Clinical Research Unit, Montreal